Literature DB >> 32960167

[Adaptive immunity against SARS-CoV-2].

Béhazine Combadière1.   

Abstract

The impact of host adaptive immune response on COVID-19 has now become a critical issue in absence of specific therapy and immunotherapies. In SARS CoV-2 infection, the immune response is thought to contribute both to the pathogenesis of the disease and to protection during its resolution. While mild cases develop an immune response that contributes to host protection, immunity of severely infected patients is a balance between harmful and protective immune responses. The severity of the disease has raised many questions about the kinetic, amplitude and the quality of adaptive immunity to the virus and its generation during the early phases of infection in severe, mild and asymptomatic patients. The role of antibody and CD4+ and CD8+ T cell responses have been studied and the development of an adaptive immunity seems to correlate with convalescence. The bioinformatics study of the T and B epitopes of coronaviruses has raised the question of the existence of cross-immunity between SARS-CoV-2 and other coronaviruses such as MERS-CoV and SARS-CoV. In this review, we discuss the adaptive immune responses and their potential roles in protection during COVID-19.
© 2020 médecine/sciences – Inserm.

Entities:  

Mesh:

Year:  2020        PMID: 32960167     DOI: 10.1051/medsci/2020168

Source DB:  PubMed          Journal:  Med Sci (Paris)        ISSN: 0767-0974            Impact factor:   0.818


  4 in total

Review 1.  Surviving the Storm: Cytokine Biosignature in SARS-CoV-2 Severity Prediction.

Authors:  Rahnuma Ahmad; Mainul Haque
Journal:  Vaccines (Basel)       Date:  2022-04-14

2.  Modulation of immunosuppressant drug treatment to improve SARS-CoV-2 vaccine efficacy in mice.

Authors:  Amy V Paschall; Ahmet Ozdilek; Sydney L Briner; Melinda A Brindley; Fikri Y Avci
Journal:  Vaccine       Date:  2021-12-31       Impact factor: 3.641

Review 3.  Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast.

Authors:  Alessio Danilo Inchingolo; Giuseppina Malcangi; Sabino Ceci; Assunta Patano; Alberto Corriero; Luigi Vimercati; Daniela Azzollini; Grazia Marinelli; Giovanni Coloccia; Fabio Piras; Giuseppe Barile; Vito Settanni; Antonio Mancini; Nicole De Leonardis; Grazia Garofoli; Giulia Palmieri; Ciro Gargiulo Isacco; Biagio Rapone; Arnaldo Scardapane; Luigi Curatoli; Nicola Quaranta; Mario Ribezzi; Maria Massaro; Megan Jones; Ioana Roxana Bordea; Gianluca Martino Tartaglia; Antonio Scarano; Felice Lorusso; Luigi Macchia; Angela Maria Vittoria Larocca; Sergey Khachatur Aityan; Silvio Tafuri; Pasquale Stefanizzi; Giovanni Migliore; Nicola Brienza; Gianna Dipalma; Gianfranco Favia; Francesco Inchingolo
Journal:  Int J Mol Sci       Date:  2022-07-30       Impact factor: 6.208

4.  Vaccination with Omicron Inactivated Vaccine in Pre-vaccinated Mice Protects against SARS-CoV-2 Prototype and Omicron Variants.

Authors:  Yuntao Zhang; Wenjie Tan; Zhiyong Lou; Yuxiu Zhao; Jin Zhang; Hongyang Liang; Na Li; Xiujuan Zhu; Ling Ding; Baoying Huang; Weimin Zhou; Yancen Guo; Zhaona Yang; Yuling Qiao; Zhenyu He; Bo Ma; Yao He; Di Zhu; Zhanhui Wang; Zhen Chang; Xue Zhao; Wei Wang; Ying Xu; Huiqin Zhu; Xiaotong Zheng; Chenlong Wang; Guangxue Xu; Guizhen Wu; Hui Wang; Xiaoming Yang
Journal:  Vaccines (Basel)       Date:  2022-07-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.